NEW YORK, Jan. 11, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of GenVec, Inc. ("GenVec" or the "Company") (Nasdaq: GNVC). Such investors are advised to contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz at email@example.com or 212-697-6484.
This investigation concerns whether GenVec and certain of its officers and/or directors have violated the Federal Securities Laws under the Securities Exchange Act of 1934 (the "Exchange Act").
On January 8, 2016, Novartis notified GenVec, a biopharmaceutical company, that it would be pausing enrollment for the CGF166 clinical trial to conduct a safety review of patient data, based on the recommendation of the trial's data safety monitoring board. The trial will continue to collect new safety and efficacy data on patients currently enrolled in the study.
Following this news, GenVec shares fell $1.11 per share, or 35%, to just $0.62 per share on January 11, 2016, during intraday trading.
If you are aware of any facts relating to this investigation, or purchased shares of GenVec, Inc., you can assist this investigation by contacting Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email firstname.lastname@example.org. Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | email@example.com
SOURCE Bronstein, Gewirtz & Grossman, LLC